Novartis AG to Acquire Regulus Therapeutics in a Landmark Deal

In a significant move that could reshape the biopharmaceutical landscape, Novartis AG has announced its agreement to acquire Regulus Therapeutics Inc. The deal, valued at up to $1.7 billion, marks a pivotal moment for both companies.

Deal Structure and Future Prospects

Under the terms of the agreement, Novartis will initiate the acquisition with a payment of $7.00 per share, totaling $0.8 billion. Additionally, Regulus shareholders are set to receive a contingent value right (CVR) that promises an extra $7.00 per share, contingent upon the regulatory approval of farabursen, Regulus' lead product candidate.

A Shared Vision for Innovation

"This partnership with Novartis represents a thrilling opportunity to advance farabursen to patients suffering from ADPKD, a condition with currently limited treatment options," expressed Jay Hagan, CEO of Regulus. He highlighted Novartis' global development and commercial prowess as key factors in bringing this potential new medicine to the forefront.

The acquisition is pending standard closing conditions and regulatory approvals, with an anticipated completion in the latter half of 2025.